Moderna (MRNA) Free Cash Flow (2018 - 2026)

Moderna (MRNA) has reported Free Cash Flow for 9 consecutive years, with -$563.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 38.94% year-over-year to -$563.0 million in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 64.36% increase from a year earlier, with the FY2025 full-year figure at -$2.1 billion, up 49.08% from the prior year.
• Free Cash Flow was -$563.0 million for Q2 2026 at Moderna, up from -$692.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $2.6 billion in Q1 2022 and troughed at -$1.7 billion in Q3 2023.
• A 5-year average of -$367.7 million and a median of -$786.0 million in 2025 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow sank 1167.48% in 2023 and soared 194.06% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at $1.6 billion in 2022, then plunged by 74.39% to $402.0 million in 2023, then declined by 24.63% to $303.0 million in 2024, then soared by 194.06% to $891.0 million in 2025, then slumped by 163.19% to -$563.0 million in 2026.
• The last three Free Cash Flow figures came in at -$563.0 million (Q2 2026), -$692.0 million (Q1 2026), and $891.0 million (Q4 2025), per Business Quant data.